Analyst Report: IDXX

1. EXECUTIVE SUMMARY

IDEXX Laboratories rose 21.85% to $671.64 on Monday 2 November 2026 after third-quarter results beat expectations and management raised full-year guidance. The company reported revenue of $1,214 million, up 10% as reported and organically, and GAAP EPS of $4.01, according to its press release. Recurring diagnostics revenue carried the quarter even though U.S. clinic visits fell. The full-year reported operating margin outlook was lowered to 32.1%-32.3% on acquisition effects, which is the one soft spot. The stock still trades below its 52-week high of $769.98 and 40.1 times forward earnings after the jump. Analyst reaction was mixed, with target cuts from JPMorgan, UBS and Jefferies, and the shares now sit above the trimmed UBS target of $627 but below the JPMorgan target of $750 and the Jefferies target of $705. The 4.30% fall on 30 October, ahead of the report, has no explanation in the research.

2. THE CATALYST

Third-quarter results came out before the open on 2 November, with the call at 8:30 a.m. ET (IDEXX press release, 2 November). The first wire headlines appeared at 11:42 UTC (Yahoo Finance headline list). The session opened at $625.00, well above the prior close of $551.21, and the shares kept climbing to a high of $673.19 and a close of $671.64 on volume of 1,976,100, which is 3.87 times the 50-session average. TheStreet attributed the move to the beat plus the raised outlook.

Full-year guidance moved as follows (IDEXX 8-K exhibit 99.1, with prior ranges from TheStreet and Benzinga):

The revenue midpoint rose about $32m, of which about $5m comes from the CoVet acquisition, and the EPS midpoint rose $0.25. Organic revenue growth guidance is now 9.3%-10%, up 60 bps at the midpoint (Motley Fool transcript).

The EPS estimate of 3.27 in the site's data does not match any figure in the research, where consensus sits near $3.71 to $3.72, so the beat is measured here against those figures.

3. COMPANY PROFILE

IDEXX develops, manufactures and distributes diagnostics for companion animal veterinary care, livestock, poultry and dairy, and water testing. It operates through the Companion Animal Group, Water Quality Products, and Livestock, Poultry and Dairy segments. Its products include point-of-care analyzers, SNAP rapid assay kits and a commercial reference laboratory network. It is in the Healthcare sector, in Diagnostics & Research, with a market cap of $52.98bn.

In the third quarter, CAG Diagnostics recurring revenue grew 11% organically, with the U.S. up about 9.6% and international up about 14% (Yahoo Finance call highlights). 24/7 Wall St. reported U.S. same-store clinic visits down an estimated 1.8%. Free cash flow was $421m in the quarter and $978m year to date, and the full-year conversion outlook is 95%-100% of net income. 24/7 Wall St. counted a seventh consecutive quarterly EPS beat.

The company has raised its EPS guide repeatedly this year: $14.29-$14.80 in February (Q4 2025 release), $14.45-$14.90 at Q1, and now $14.96-$15.16.

4. DEEP DIVE ANALYSIS

Do fundamentals justify the move? The beat and raise are documented and the guidance steps are consistent with a pattern of upward revisions. The size of the one-day gain is large for a company with a 40.1 forward multiple. Part of it looks like a reversal of the 30 October fall: the close of $671.64 compares with $575.98 on 29 October, a gain of 16.6% over the two sessions. That arithmetic is the writer's own calculation from the daily closes. The research found no explanation for the 30 October drop on about 3x normal volume, so whether it was company-specific or sector news remains open.

Peers. Health care equipment peers rose between 1.12% (ISRG) and 5.57% (BSX) over the period, while the S&P 500 fell 0.51%. The research found no sector news for 2 November, so IDEXX's move is company-specific in the evidence available. Peer strength may have added a little support (inference).

Analyst reaction. The research relies on two aggregator sites for these actions, and they should be confirmed against broker notes.

KeyBanc cited expected softness in U.S. vet visits over the next couple of years and called the stock fairly valued. MarketBeat's pre-report average target was about $721.67 across 14 analysts, a range of $627 to $823. The close of $671.64 is below that average and above the UBS target of $627, but below the Jefferies target of $705.

Bull case. Recurring diagnostics growth of 11% organic continues without a clinic visit recovery, as management argued on the call when a JPMorgan analyst questioned how the organic outlook rose to nearly 10% with visits flat to lower. Guidance has risen at each of three reports this year, margins expanded 100 bps in the quarter, and the MultiCue Dx analyzer is a new product to come.

Bear case. Visits are falling, KeyBanc expects softness for years, the full-year reported operating margin outlook was cut, and several brokers lowered targets even as the shares jumped. After a 27.43% gain over 20 sessions, the shares price in much of the good news.

5. TECHNICAL SNAPSHOT

The close of $671.64 is above the 50-day average of $536.56 and the 200-day average of $572.42, having cleared both in one session. It sits 12.8% below the 52-week high of $769.98 set on 26 November 2025 and well above the 52-week low of $500.61 from 11 September 2026. Volume of 1,976,100 was 3.87 times the 50-session average and followed 1,173,500 on 30 October, so heavy participation backed both sessions. The nearest support is the prior close of $575.98 from 29 October, with the 200-day average just below it at $572.42. The latest close is the highest in the table, so no resistance level appears in the recent closes, and the 52-week high is the next reference above.

6. RISK FACTORS

• U.S. clinic visits fell an estimated 1.8%, and KeyBanc expects softness over the next couple of years.
• The reported operating margin outlook was lowered to 32.1%-32.3%, with 24/7 Wall St. estimating a CoVet drag of about 30 bps across Q3 and Q4.
• Target cuts from JPMorgan, UBS and Jefferies came on the same day as the rally.
• The unexplained 30 October drop leaves open whether an unidentified issue exists.
• After a one-day gain of 21.85%, the shares can retrace part of the move.
• The research flags unverified details: the CEO's name (Mike Erickson in the Q3 release, Jay Mazelsky in the Q1 release) and whether the acquisition was CoVet or ezyVet.

Dated catalysts. The Q4 2026 earnings date was not found in the research, and the site's "next earnings" field of 2 November refers to the report just released. IDEXX will show MultiCue Dx at an investor session at VMX on Monday 18 January (year not stated, presumably 2027, per 24/7 Wall St.).

7. ACTIONABLE OUTLOOK

Short term (1-2 weeks). The shares stand 16.6% above their 29 October close, and the first test is whether they hold above $575.98 and the 200-day average of $572.42. Further broker target revisions, which will likely follow, set the tone. Continued volume well above the 510,356 average would indicate institutional buying, and a fade to normal volume would indicate profit-taking.

Medium term (1-3 months). The price depends on whether recurring revenue growth holds near 10% while visits stay weak. Guidance of $14.96-$15.16 EPS puts the shares at roughly 44 times the guidance midpoint (own calculation: $671.64 divided by $15.06), which leaves less room for disappointment than before the report. A move toward the $705 to $750 targets of Jefferies and JPMorgan would need evidence of margin recovery.

Long term. The thesis of a recurring diagnostics franchise growing independently of visit counts has support from three consecutive guidance raises and the 11% organic growth in CAG Diagnostics recurring revenue. The visit slump and acquisition-related margin drag remain the items to monitor. This is analysis only and not personal financial advice.